[1]王晓芳.低分子肝素治疗COPD合并Ⅱ型呼吸衰竭的临床疗效[J].医学信息,2019,(19):155-157.[doi:10.3969/j.issn.1006-1959.2019.19.051]
 WANG Xiao-fang.Clinical Efficacy of Low Molecular Weight Heparin in the Treatment of COPD with Type II Respiratory Failure[J].Medical Information,2019,(19):155-157.[doi:10.3969/j.issn.1006-1959.2019.19.051]
点击复制

低分子肝素治疗COPD合并Ⅱ型呼吸衰竭的临床疗效()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年19期
页码:
155-157
栏目:
药物与临床
出版日期:
2019-10-01

文章信息/Info

Title:
Clinical Efficacy of Low Molecular Weight Heparin in the Treatment of COPD with Type II Respiratory Failure
文章编号:
1006-1959(2019)19-0155-03
作者:
王晓芳
(天津市职业病防治院综合内科,天津 300011)
Author(s):
WANG Xiao-fang
(Institute of Internal Medicine,Tianjin Occupational Disease Prevention and Control Institute,Tianjin 300011,China)
关键词:
慢性阻塞性肺疾病Ⅱ型呼吸衰竭低分子肝素
Keywords:
Chronic obstructive pulmonary diseaseType II respiratory failureLow molecular weight heparin
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2019.19.051
文献标志码:
A
摘要:
目的 探讨慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者联合使用低分子肝素治疗的临床疗效。方法 选取2016年3月~2019年3月我院收治的58例慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者作为研究对象,随机分为观察组与对照组,各29例。对照组采用呼吸兴奋剂尼可刹米治疗,观察组在对照组基础上联合低分子肝素治疗。比较两组患者的临床疗效、动脉血气指标(PaO2、PaCO2)及肺功能指标(FEV1、FEV1/FVC)。结果 观察组总有效率高于对照组(96.55% vs 72.41%),差异有统计学意义(P<0.05);观察组PaCO2低于对照组[(56.13±9.07)mmHg vs(62.13±10.01)mmHg]、PaO2高于对照组[(71.06±8.22)mmHg vs (65.38±9.98)mmHg] ,差异有统计学意义(P<0.05);观察组FEV1、FEV1/FVC分别为(46.57±11.46)L、(42.78±10.45)%,高于对照组的(38.61±10.66)L、(36.22±9.88)%,差异有统计学意义(P<0.05)。结论 低分子肝素治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者的疗效显著,可有效改善患者肺功能及动脉血气指标,提高肺通气量。
Abstract:
Objective To investigate the clinical efficacy of low molecular weight heparin in patients with chronic obstructive pulmonary disease and type II respiratory failure.Methods A total of 58 patients with chronic obstructive pulmonary disease and type II respiratory failure admitted to our hospital from March 2016 to March 2019 were randomly divided into observation group and control group, 29 cases in each group. The control group was treated with the respiratory stimulant nikethamide, and the observation group was treated with low molecular weight heparin on the basis of the control group. The clinical efficacy, arterial blood gas index (PaO2, PaCO2) and lung function index (FEV1, FEV1/FVC) were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group (96.55% vs 72.41%),the difference was statistically significant (P<0.05). The PaCO2 of the observation group was lower than that of the control group [(56.13±9.07)mmHg vs (62.13±10.01)mmHg] PaO2 was higher than the control group [(71.06±8.22) mmHg vs (65.38±9.98) mmHg], the difference was statistically significant (P<0.05);The FEV1 and FEV1/FVC of the observation group were (46.57±11.46)L and (42.78±10.45)%, which were higher than those of the control group (38.61±10.66)L and (36.22±9.88)%,the difference was statistically significant (P<0.05).Conclusion Low molecular weight heparin is effective in the treatment of patients with chronic obstructive pulmonary disease and type II respiratory failure. It can effectively improve lung function and arterial blood gas index and improve lung ventilation.

参考文献/References:

[1]陈润杉,陈检娣.低分子肝素联合纳洛酮治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的疗效观察[J].中国医院用药评价与分析,2017,17(10):1322-1323. [2]张海明,李信杰,张旋.低分子肝素联合纳络酮对 AECOPD合并Ⅱ型呼吸衰竭患者肺功能及用药安全性的影响[J].黑龙江医药,2017,30(1):118-120. [3]赵志芳.纳洛酮联合无创呼吸机治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的临床疗效观察[J].海峡药学,2017,14(29):117. [4]黄曼,贾钦尧,许冀,等.多沙普仑联合双水平气道正压通气治疗慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭患者的临床疗效[J].实用心脑肺血管病杂志,2018,26(1):114-117. [5]吴涛,张华兵,徐文中.BiPAP呼吸机联合尼可刹米治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的疗效[J].医学理论与实践,2017,30(20):3020-3022. [6]徐婕,曾龙飞,龚建祖,等.低分子肝素钙皮下注射治疗慢性阻塞性肺疾病急性加重期合并肺心病的疗效[J].实用医学杂志,2018,34(9):142-145. [7]王盟,张秀芹,杨静,等.纳洛酮对慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者血清炎症因子水平及血气分析的影响[J].现代生物医学进展,2017,17(20):3936-3939. [8]孟素秋,袁继印,杨文宝,等.低分子肝素配合双水平无创正压通气对COPD合并Ⅱ型呼吸衰竭患者肺功能及氧代谢的影响[J].中国医师杂志,2017,19(4):614-616.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
 ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(19):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
 CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(19):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
 WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,(19):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
 LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(19):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
 LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,(19):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
 ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(19):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
 JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,(19):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
 ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(19):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
 ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(19):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 2019-10-01